Talaris pulls off $150M IPO to tackle organ rejection, autoimmune disorders

Another day, another biotech IPO. This time, it's cell therapy player Talaris Therapeutics, which raised $150 million in a Nasdaq debut to fuel the company's lead asset, an off-the-shelf cell therapy it hopes will transform the standard of care in organ transplant, as well as some disorders of the blood, immune system and metabolism.